VF
TRVI icon

Virtu Financial’s Trevi Therapeutics TRVI Stock Holding History

Virtu Financial’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,995
Closed -$27K – 2108
2022
Q4 		$27K Buy
+13,995
New +$27.6K ﹤0.01% 1204
2022
Q2 		– Sell
-20,055
Closed -$44K – 2083
2022
Q1 		$44K Buy
+20,055
New +$20.8K ﹤0.01% 1168

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Virtu Financial's TRVI Position: Q1 2023 in Review

Virtu Financial sold out of Trevi Therapeutics (TRVI) in Q1 2023, closing a stake of 13,995 shares — an estimated $27K sold.

Virtu Financial first reported a position in TRVI in Q1 2022 and held it in 2 quarters. The position peaked at $44K in Q1 2022. 36 funds tracked by Wall St. Rank hold TRVI as of Q1 2023.

  • Virtu Financial reported no remaining Trevi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Virtu Financial sold 13,995 Trevi Therapeutics shares in Q1 2023, an estimated $27K.
  • Virtu Financial first reported a position in Trevi Therapeutics in Q1 2022 and held it in 2 quarters.
  • Virtu Financial's Trevi Therapeutics position peaked at $44K in Q1 2022.
  • 36 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2023.

Based on Virtu Financial's 13F filing for Q1 2023, filed 1 May 2023.